Assembly Biosciences (ASMB) Stock Price, News & Analysis

Company Overview

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $21.00 to $23.97
• 50-Day Range: $15.20 to $23.97
• 52-Week Range: $7.75 to $23.97
• Volume: 480,844 shs
• Average Volume: 38,031 shs
• Market Capitalization: $183.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $33.00
• Consensus Rating: Moderate Buy

Assembly Biosciences Stock Analysis - MarketRank™

Assembly Biosciences scored higher than 76% of companies evaluated by MarketBeat, and ranked 233rd out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Assembly Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Assembly Biosciences has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Assembly Biosciences are expected to decrease in the coming year, from ($6.87) to ($7.64) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Assembly Biosciences is -4.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Assembly Biosciences is -4.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Assembly Biosciences has a P/B Ratio of 10.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.76% of the float of Assembly Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Assembly Biosciences has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Assembly Biosciences has recently increased by 0.33%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Assembly Biosciences does not currently pay a dividend.

Dividend Growth

Assembly Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.71

Percentage of Shares Shorted

0.76% of the float of Assembly Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Assembly Biosciences has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Assembly Biosciences has recently increased by 0.33%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.69

News Sentiment

Assembly Biosciences has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Assembly Biosciences this week, compared to 5 articles on an average week.

MarketBeat Follows

3 people have added Assembly Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Assembly Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.30% of the stock of Assembly Biosciences is held by insiders.

Percentage Held by Institutions

Only 19.92% of the stock of Assembly Biosciences is held by institutions.

ASMB Stock Analysis - Frequently Asked Questions

How have ASMB shares performed this year?

Assembly Biosciences' stock was trading at $15.78 at the beginning of 2025. Since then, ASMB stock has increased by 51.9% and is now trading at $23.97.

How were Assembly Biosciences' earnings last quarter?

Assembly Biosciences, Inc. (NASDAQ:ASMB) issued its quarterly earnings data on Wednesday, August, 6th. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.73) by $0.40. The biopharmaceutical company had revenue of $9.63 million for the quarter, compared to the consensus estimate of $5.30 million. Assembly Biosciences had a negative net margin of 117.20% and a negative trailing twelve-month return on equity of 149.01%.

When did Assembly Biosciences' stock split?

Assembly Biosciences's stock reverse split before market open on Monday, February 12th 2024.The 1-12 reverse split was announced on Monday, February 12th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Who are Assembly Biosciences' major shareholders?

Top institutional shareholders of Assembly Biosciences include Geode Capital Management LLC (0.67%) and Palumbo Wealth Management LLC (0.24%). Insiders that own company stock include Alexander Schornstein, John G Mchutchison, Jason A Okazaki, Nicole S White, Jeanette M Bjorkquist and Michael Houghton.
View institutional ownership trends.

How do I buy shares of Assembly Biosciences?

Shares of ASMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Assembly Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Assembly Biosciences investors own include Waste Connections (WCN), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), AU Optronics (AUOTY), American Water Works (AWK), The RMR Group (RMR) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 8/06/2025
• Today: 8/09/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - GENERIC DRG
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ASMB
• CIK: 1426800
• Web: www.assemblybio.com
• Phone: (833) 509-4583
• Fax: 646-706-5101
• Employees: 100
• Year Founded: 2005

Price Target and Rating

• Average Price Target for Assembly Biosciences: $33.00
• High Price Target: $35.00
• Low Price Target: $31.00
• Potential Upside/Downside: +37.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$40.18 million
• Net Margins: -117.20%
• Pretax Margin: -117.42%
• Return on Equity: -149.01%
• Return on Assets: -39.04%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.64
• Quick Ratio: 2.05

Sales & Book Value

• Annual Sales: $28.52 million
• Price / Sales: 6.42
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.37 per share
• Price / Book: 10.11

Miscellaneous

• Outstanding Shares: 7,640,000
• Free Float: 7,233,000
• Market Cap: $183.13 million
• Optionable: Optionable
• Beta: 0.64